Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

targeting inflammation and bronchodilation in COPD patients. Moreover, Verona Pharma has partnered with Ritedose for the development and manufacturing of Ohtuvayre.

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.

Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD populationLONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GlobalData has suggested that Ohtuvayre could have a transformative role to play in the management of COPD patients who are prone to exacerbations, sudden flare-ups in symptoms that signal the ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in more than 20 years.

The success of Dupixent has demonstrated the viability of biologics in COPD. (Image Credits: Pixabay) AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be ...